Innovus Pharmaceuticals Inc (NASDAQ:INNV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “Innovus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. It delivers non-prescription medicine and consumer care products to improve men’s and women’s health and vitality. It has a robust portfolio of sexual dysfunction treatments, cough, cold, respiratory disease treatments and pain management medication, as well as skin care products. Its male and female sexual health and vitality products include Zestra (R) to increase desire, arousal, and satisfaction in women; EjectDelay (R) for treating premature ejaculation; Sensum+ (TM) that increases penile sensitivity; Zestra Glide (R); and Vesele (R) to maximize nitric oxide beneficial effects on sexual functions and brain health. Innovus Pharmaceuticals, Inc. is based in San Diego, California. “

Innovus Pharmaceuticals (NASDAQ INNV) traded down 4.598% on Tuesday, reaching $0.083. 180,928 shares of the company’s stock traded hands. Innovus Pharmaceuticals has a 52-week low of $0.08 and a 52-week high of $0.39. The firm’s 50 day moving average price is $0.10 and its 200 day moving average price is $0.11. The firm’s market capitalization is $12.56 million.

Innovus Pharmaceuticals (NASDAQ:INNV) last posted its quarterly earnings results on Monday, August 14th. The company reported ($0.01) earnings per share for the quarter. The business had revenue of $2.04 million for the quarter. Innovus Pharmaceuticals had a negative return on equity of 178.65% and a negative net margin of 55.63%. On average, analysts predict that Innovus Pharmaceuticals will post ($0.07) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/24/innovus-pharmaceuticals-inc-innv-stock-rating-upgraded-by-zacks-investment-research.html.

About Innovus Pharmaceuticals

Innovus Pharmaceuticals, Inc is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners.

Get a free copy of the Zacks research report on Innovus Pharmaceuticals (INNV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innovus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.